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ABSTRACT
This chapter reviews the options for effective public sec-
tor management of intellectual property (IP) in the life 
sciences, focusing on the need for a judicious, pragmatic 
choice of options along two axes: (1) deployment of 
exclusive rights over technology and (2) use of market 
mechanisms to bring a new technology to the public. 
The essence of public sector IP management is finding 
the right settings along these two axes that will deliver 
tangible outcomes in line with defined public-interest 
objectives. Experience shows that ex ante assumptions 
about how to gain optimal leverage from exclusive rights, 
and the appropriate degree of reliance on market mecha-
nisms, are unlikely to serve a public sector IP manager 
well. In clarifying objectives and the practical means of 
achieving them, pragmatic coordination between the 
practical and policy levels is essential. Public sector IP 
managers are more likely to be assessed against public 
interest expectations than their private sector colleagues. 
In IP management in the life sciences, policy and prac-
tice are ultimately two sides of the same coin; practi-
tioners cannot hope, expect, or plan to operate outside 
the broader policy perspective. Policy-makers therefore 
need to consider the actual practice of IP management 
when assessing a policy framework for innovation in 
the life sciences. IP managers should be open to using 
legal mechanisms flexibly for inclusion, or exclusion, as 
required to achieve their goals. Finally, managers should 
seek mechanisms to pragmatically structure and promote 
partnerships with those who have the resources necessary 
to bring life-sciences innovation to the public. Such part-
nerships may be centered in the public, philanthropic, or 
private sectors, but more likely fall into a hybrid mix of 
these categories.
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1. OveRview And COnTexT
1.1 Toward policy-rich practice and 
practice-informed policy
Researchers, technology managers, and intellec-
tual property (IP) advisors who work in the life 
sciences and who use the IP system are not oper-
ating in a policy-neutral, strictly technical envi-
ronment. An overarching public interest in life-
sciences innovation means that the accumulated 
impact of many seemingly independent, individ-
ual choices will in fact have implications for how 
the IP system is perceived by policy-makers and 
will therefore help to determine policy directions. 
The practical choices made when managing IP 
rights therefore ultimately influence public policy 
debate. Indeed, given public expectations for life-
sciences innovation, choices over when and how 
to exercise IP rights are inevitably assessed from a 
policy point of view. 
Practitioners need to be sensitive to the poli-
cy environment and alert to the debates that swirl 
around two related aspects of public concerns: 
(1) the impact of life-sciences developments in 
themselves and (2) the impact when intellectual 
property is applied to life-sciences innovation. 
While this may frustrate legally trained practitio-
ners, how the IP system is used, and the perceived 
equities of access to the benefits of a life-sciences 
CHAPTER 3.6
Taubman A and R Ghafele. 2007. Public Sector IP Management in the Life Sciences: Reconciling Practice and Policy—Per-
spectives from WIPO. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Prac-
tices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.
ipHandbook.org.
© 2007. A Taubman and R Ghafele. Sharing the Art of IP Management: Photocopying and distribution through the Internet 
for noncommercial purposes is permitted and encouraged.
Public Sector IP Management in the Life Sciences:  
Reconciling Practice and Policy— 
Perspectives from WIPO
Antony tAubmAn, Acting Director and Head, Global IP Issues Division, Life Sciences Program, 
World Intellectual Property Organization, Switzerland
RoyA GhAfele, Economic Consultant, Global IP Issues Division, Life Sciences Program,  
World Intellectual Property Organization, Switzerland
TAUBMAN & GHAFELE
230 | HANDBOOK OF BEST PRACTICES
technology, can affect public perceptions of the 
legitimacy of that technology. Juma and Konde 
write:
Resistance to new technologies is likely to be re-
duced by changing perceptions of access to the new 
technologies as well as to their markets. This has not 
been the case with agricultural biotechnology, which 
involves worldwide exports with the potential for 
product displacement, while leaving wide margins 
of uncertainty for technology followers.1
Moreover, the policy debate cannot oper-
ate in isolation from the practical realm. Policy-
makers need a robust, practical understanding of 
the technologies concerned, of the nature of life-
sciences innovation, of the overall trends in the 
IP landscape, and of the real-world impact of the 
actual exercise of IP rights. Only then can policy-
makers effectively balance concerns about equity 
of access with the proper exercise of exclusive 
rights. Optimal policy choices require the widest 
range of distilled, neutral empirical information 
about the use of intellectual property in relation 
to key life-sciences technologies. Indeed, the ex-
perience of practitioners contributes valuable in-
sights needed to guide and buttress policy debate 
over the future of life-sciences innovation.
1.2 Resolving the paradox: public  
interest through private rights
Reconciling the public policy role of the IP system 
with the management and exercise of private IP 
rights addresses the central paradox of IP policy: 
what legal exclusions from the public domain are 
required to promote the public interest? And how 
can those exclusive rights, once granted, be best 
deployed for IP law to function as a public policy 
tool? Life sciences concern the basic human needs 
of food, health, and a safe environment. How 
then can IP rights be best managed to promote 
public welfare by making available the fruits of 
life-sciences innovation and spurring economic 
development? These benefits arise not from the 
mere presence of a formal system of assessing, 
granting, and enforcing IP rights, but from the 
judicious, skillful application of these legal mech-
anisms in practice. Positive welfare gains from 
IP mechanisms emerge from an accumulation 
of individual choices, not just from the abstract 
process of shaping a legislative framework This 
is most directly illustrated by the experience of 
managing rights held by public sector institutions, 
which can be held more immediately responsible 
than their private sector counterparts for securing 
tangible benefit gains directly from public invest-
ment in research and development. Thus, we see 
the emergence of public sector IP management 
as a distinct subset within the broader discipline 
of IP management. For instance, pharmaceutical 
public-private partnerships “must be as aggressive 
in the way they use IP as any commercial unit, but 
for a different purpose—namely to pursue their so-
cial objective of getting quality, affordable products 
to developing country patients.”2
The optimal implementation of IP rights re-
quires a practical understanding of the full range 
of options for exercising exclusive rights and a ca-
pacity to assess and implement those options as 
part of a broader strategy. IP rights are exclusive 
in their formal legal character, but the modes of 
exercising such rights are highly diverse and will 
correspond to an institution’s broader objectives. 
A predetermined license template, for example, 
will not lead to best practice in IP management 
in the life sciences, because its use may effectively 
foreclose the full range of choices available and 
preempt the objective assessment of the implica-
tions of each option. A good manager will instead 
judiciously use IP mechanisms to leverage the re-
sources needed and obtain the freedom to oper-
ate, while prudently assessing the likely impact of 
various forms of IP rights exploitation. 
Workable public sector–management models 
do not normally entail an exclusive reliance on re-
lease into the public domain nor on wholly exclu-
sive licensing. While it is rare to see a life-sciences 
product delivered without some engagement of 
private sector actors responding to market signals, 
it is usually misleading to set the full product de-
velopment pipeline wholly in the public or private 
sectors. Given especially the necessarily stringent 
regulatory environment confronting the life sci-
ences and the need to garner resources for the full 
product development process, investments will 
likely draw on both public and private resources. 
Therefore, rather than employing simple public/
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private or open/exclusive labels, the full range of 
options available to public sector IP managers can 
be more usefully analyzed along two continuums: 
(1) degree of exclusivity, ranging from defensive 
publishing in the public domain through open 
source or commons-based constructs, and nonex-
clusive and exclusive licensing, to direct exploita-
tion of exclusive rights; and (2) degree of market 
engagement, from pure research, through mak-
ing some use of private resources in the develop-
ment pipeline, to various modes of outsourcing 
product development and the dissemination of 
a proven life-sciences technology, including spi-
noffs and transfer of rights to private firms. Even 
if a public sector IP manager’s core responsibility 
is to deliver welfare gains to the public in the form 
of accessible new life-sciences technologies, she or 
he is likely to have to assess the full range of op-
tions across these two spectra when formulating 
a practical strategy. These options are presented 
schematically in Figure 1 (which is also further 
discussed in section 4.2 below).
1.3 The meaning of global 
intellectual property
Participation in the international patent system 
continues to grow and diversify in three overlap-
ping ways, each with direct ramifications for the 
field of public sector IP management:
1. Greater geographical and cultural diversity. 
Membership in the Patent Cooperation 
Treaty (PCT) has shifted from an early 
Figure 1: Public Interest IP Management Goes Beyond Licensing Arrangements
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preponderance of developed and transi-
tional economies to a clear majority of de-
veloping countries. In terms of the actual 
use of the system, patent applicants from 
the developed world continue to predomi-
nate, but current trends reveal double-digit 
growth, sustained over five years or more, 
on the part of certain key developing coun-
tries. This trend, if sustained in the medium 
term, would significantly shift the center of 
international patent activity. PCT interna-
tional applications received from develop-
ing countries in 2005 rose 24.8% com-
pared to 2004, and constituted 6.9% of all 
filings. China, Mexico, and the Republic of 
Korea are among those countries register-
ing double-digit percentage increases in use 
of the PCT.3 (Figure 2)
2. Greater use of the system by public sec-
tor and not-for-profit entities. In the 
life-sciences domain, these are as di-
verse as India’s Council of Scientific and 
Industrial Research, Empresa Brasileria 
de Pesquisa Agropecuaria (Embrapa), the 
Korea Research Institute of Bioscience 
and Biotechnology, the International 
Aids Vaccine Initiative, the Medicines for 
Malaria Venture, and CAMBIA.
3. Growth in use of the system in life-scienc-
es technologies stronger than the general 
trend. For instance, PCT publications in 
the technical field represented by IPC Class 
A61K (Preparations for Medical, Dental, 
or Toilet Purposes) rose 5.1% in 2005. 
In the next highest field (G06F—Electric 
Digital Data Processing) the growth rate 
was 4.6%.4
Public sector users of the patent system who 
are working in the life sciences face practical 
questions about how to manage a patent estate 
to advance their institutional objectives. While 
this has been the subject of a longstanding de-
bate in the developed world, it is increasingly a 
practical issue for developing countries as well. 
The rate of public sector patenting in life-sciences 
research in developing countries is growing expo-
nentially. These countries are, of course, starting 
from a small base, so the actual impact will be 
felt over time as international activity translates 
into distinct national rights. It is certain, how-
ever, that government agencies and other public 
sector institutions in developing countries will be 
increasingly responsible for managing a growing 
stock of life-sciences intellectual property result-
ing from investment of public resources, or from 
combined private and public sector inputs. These 
governments will assume the task in light of their 
overarching responsibility to promote the public 
interest through the management of this intel-
lectual property. Doing so entails working on 
a broader canvas than the mainstream manage-
ment of intellectual property the essential focus 
of which is to promote commercial outcomes.
Such social or institutional responsibilities 
require that public sector IP managers develop 
and apply practical skills to manage intellectual 
property effectively. They may need to look be-
yond conventional, private sector methodologies 
to find appropriate ways of managing intellec-
tual property to ensure the desired public inter-
est outcomes. These might include ensuring the 
development and effective dissemination of new 
technologies to the public (for example, new 
pharmaceuticals), promoting economic and social 
development, creating skilled jobs, or enhancing 
urgent research funding.
Effectively managing public interest IP is a 
task that requires judgment and acute sensitivity, 
acutely so in life-sciences domains. It requires ad-
vanced skills. There is a wide spectrum of possible 
approaches, and there are many distinct objectives 
that may be pursued. IP management to produce 
public health outcomes is particularly demand-
ing, yet vitally important for the public interest. 
1.4 Choices for public sector IP management 
While often debated in abstract terms, the impact 
of IP laws and IP rights is ultimately determined 
by a series of practical, yet critical, choices. For 
the public sector, these choices are increasingly 
guided by IP management policies. Tom Ogada 
has categorized these choices in terms of:
• Who owns the intellectual property gen-
erated by government-funded research 
activities? 
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• How will revenues/benefits from the com-
mercialization of intellectual property be 
shared between the researcher/inventors, 
the department, the institution, and gov-
ernment funding providers? 
• Which, if any, government rights/stipula-
tions are attached to the commercialization 
of intellectual property generated under 
government-funded research? 
• In the case of privately funded research, who 
will own any resulting intellectual property? 
• Will spinout companies or licensing con-
tracts be used to transfer technology to the 
private sector for commercialization? 
• Who will manage IP assets, including the 
negotiation of licenses and royalty sharing? 
• To what extent will the institution encour-
age research commercialization through 
entrepreneurial activity? 
• How will the costs of IP protection and 
maintenance be paid? 
• How should any invention disclosure pro-
cedure be managed? 
• How will conflicts of interest between 
teaching/research duties and commercially 
driven projects be handled?
To assist public sector IP managers and 
policy-makers in making these decisions, Ogada 
has authored Guidelines on Developing Intellectual 
Property Policy for Universities and R&D 
Institutions in African Countries.5 Other relevant 
Figure 2: PCT Applications of Select Research Centers 
in India, the Republic of Korea and South Africa
Source: PCT Patent Statistics, 2006.
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World Intellectual Property Organization 
(WIPO) resources include:
• Successful Technology Licensing. This booklet, 
written for use by business managers, technol-
ogy managers, and scientists who deal with 
licensing questions, aims to help its readers 
negotiate win-win licensing agreements, in 
which all parties receive and exchange ap-
proximately equal benefits and value. 
• Exchanging Value—Negotiating Technology 
Licensing Agreements: A Training Manual. 
This text focuses on the practical business 
needs and concerns of nonspecialists who 
have to deal with licensing in or licensing 
out of technology. The manual includes an 
outline for a program schedule and practical 
guidelines for creating and managing teams/
groups for conducting mock negotiations. 
(These are from a five-day practical workshop 
on negotiating technology licenses, includ-
ing a case study on tuberculosis vaccines.) 
• Advanced Distance Learning Course on 
Biotechnology and Intellectual Property. This 
addresses aspects of patenting biotechno-
logical inventions and the plant breeder’s 
rights systems, as well as IP in research and 
development, and the management and 
practical use of IP rights.
2. BiOmediCAl innOvATiOn  
And develOpmenT
2.1 Capturing the benefits of 
indigenous innovation
Concentrating on technology transfer as a key 
innovation strategy, mainstream discourse on in-
novation and development tends to cast develop-
ing countries as recipients of technology produced 
elsewhere. While access to foreign technology is 
clearly integral to development, it is increasingly 
important to focus directly on capturing the in-
digenous innovation potential of developing coun-
tries.6 Given that developing countries hold signif-
icant traditional knowledge and genetic resources, 
this arguably applies in the life sciences more than 
in any other field. At least one of the lessons of 
the biopiracy debate is the need to ensure that 
custodian countries derive social and economic 
benefits from these vital feedstocks for life-science 
research. Accordingly, delivering on the promise 
of life-sciences innovation requires outcomes tai-
lored to the circumstances of individual countries. 
This means democratizing innovation to address 
neglected diseases that disproportionately afflict 
the developing world, or to respond to the agro-
nomic, environmental, and nutritional context of 
developing country agriculture.
Many developing countries possess the hu-
man capital necessary for life-sciences innovation, 
and they seek the practical pathways to realize this 
potential, not only from the point of view of eco-
nomic development, but also from the broader 
perspective of public welfare. For instance, local 
health practitioners have extensive practical expe-
rience in traditional knowledge systems, as heirs 
of generations of “clinical trials.” In dealing with 
endemic diseases, the knowledge reserves of the 
health practitioners need to be drawn on more 
systematically as part of a sustainable, bottom-
up approach to development. The recent launch 
of the South African Indigenous Knowledge 
Systems (Box 1) places traditional knowledge 
policy squarely in the context of innovation pol-
icy and the equitable sharing of benefits.
2.2  Innovation and intellectual  
property—the practical context
Debate continues over the overall role and impact 
of IP protection in relation to meeting the twin 
goals of fostering innovation and promoting the 
effective dissemination of the fruits of innova-
tion.8 Adopting the approach of this Handbook, 
this chapter does not enter into the debate be-
yond pointing out that the policy context is a 
highly dynamic one, greatly influenced by feed-
back from the actual and perceived impact of the 
accumulated choices of IP managers. It is clear 
that the effectiveness of the patent system for at-
taining these objectives depends on its practical 
context, which can be addressed on three levels: 
1. the regulatory and administrative level (dis-
cussed in more detail below)
2. the level of skills and capacity (As a com-
plex policy mechanism, the patent system 
requires skilled operators.)
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3. the level of individual users of the system: 
applicants, opponents, licensees, advisors, 
and advocates, with a special focus here on 
public interest users
At the regulatory and administrative level, 
the key elements of a practically effective system 
include:
• patent quality, construed here as the great-
est possible convergence between actual 
patenting outcomes and the public inter-
est as delineated in the principles of patent 
law, especially the conventional criteria for 
patentability
• the transparency, clarity, and predictability 
that effective administration provides in 
terms of the practical accessibility of timely 
patent information, the clarity of scope and 
title, and functional patent quality
• practical equity of access to the system, so 
that the skew of accessibility that favors al-
ready dominant private sector players can 
be reduced
• persuasive deterrents and remedies against 
the misuse of patent rights once granted
2.3 System functionality and the capacity  
to make the system function
In sum, much of the public welfare impact of the 
system and actual delivery of equity depend on 
system functionality—not merely on the formal 
legal settings that form the focus of international 
debate. Effective functionality depends on de-
ploying three special skill sets:
1. The legal and policy skills required to draft 
and implement suitable legislation and 
policy mechanisms within the framework 
of international standards but also tailored 
to national needs and priorities
2. The technological know-how and legal 
skills required to draft patent documenta-
tion and to objectively assess the validity 
and legitimate scope of patents in patent 
examination and judicial processes
3. Technological management skills, includ-
ing valuation of disclosed innovations 
in light of institutional goals (not just in 
terms of commercial value), assessment of 
potential technology development and dis-
semination pathways, and the formulation 
of patenting and licensing strategies 
As a rough generalization, capacity-building 
processes in developing countries have tended to 
focus on each of these skill sets in turn, beginning 
with a top-down legislative perspective. This has 
been most conspicuous in the decade of the im-
plementation of the Agreement on Trade-Related 
Aspects of Intellectual Property Rights (TRIPS). 
This sequence of shifting priorities for capacity 
building reflects a natural evolution from a legalis-
tic view of implementation and a reactive, or defen-
sive, posture followed by a greater concentration on 
building administrative and institutional capacity, 
South Africa’s Indigenous Knowledge Systems (IKS) Policy aims at “positive synergy between South 
African IKS and the South African National System of Innovation” through: 
• the creation of a legal benefit-sharing framework
• the establishment of a formal recording system for IK 
• legislation to ensure minimum standards in information and material transfer agreements 
with respect to IK research
• the promotion of IK links with the science base by means of targeted funding instruments
• amendments to patent legislation to enforce IK prior art declaration
Source: WIPO.7
Box 1: Traditional Knowledge and Innovation in South Africa
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to the current growing emphasis on strategies that 
practically and proactively capture direct benefits 
from indigenous research capacity and comparative 
advantage in knowledge resources. This Handbook 
is emblematic of the culmination of this last trend. 
But capacity building must continue on these three 
tracks in parallel, mutually informing and reinforc-
ing one another, especially in the life sciences. In 
particular, the practical view from the bottom up 
should inform the view from the top down in a re-
spectful dialogue between policy-conscious practi-
tioner and practically informed policy-maker.
2.4 The policy impact of effective users
Clearly, it is the central role and responsibility of 
administrators to promote the effective and efficient 
functioning of the system as a system. But users are 
not just customers of the system; they function as 
active agents engaged in safeguarding patent quali-
ty: “users” have responsibilities as patent applicants, 
as patent opponents, as litigants, and as licensors 
or licensees. Adversarial legal processes have shaped 
much of the important detail of patent law. The 
costs and limitations of the existing administrative 
and legal systems have led to calls to more system-
atically include a user perspective on patenting out-
comes.9 The growth in life-sciences patent filings by 
government agencies and public sector institutions 
may lead to further blurring of the boundaries be-
tween administration and knowledge management 
within public sector agencies and to the implemen-
tation of a broader, more holistic array of innova-
tion policy settings. Ideally, the responsibility to ef-
ficiently manage IP portfolios will be understood in 
relation to the broader responsibility to contribute 
to public policy outcomes. This extra layer of opera-
tional and ethical complexity creates a distinct chal-
lenge for the public sector IP manager. Managers of 
private sector IP portfolios in the life sciences may 
need to consider ethical and social constraints, such 
as professional ethics and corporate social respon-
sibility programs, but this chapter concentrates on 
the public sector manager.
2.5 The public sector IP manager  
as a system user 
Since the informed, judicious management of life-
sciences IP is the most realistic way of boosting 
actual availability of vital life-sciences technolo-
gies, the public sector IP manager has fundamen-
tally important responsibilities. IP management 
is a practical craft, not a rigid legal discipline, 
difficult to capture in terms of checklists and 
licensing templates. This section reviews best 
practice for public sector IP managers in life-sci-
ences technologies. The discussion focuses on two 
broad categories of responsibility: policy-orient-
ed, or systemic, and outcome-oriented, or practi-
cal. Experience has shown that early assumptions 
about the right mix of exclusivity or openness of 
access, and the right proportion of a reliance on 
public resources and an engagement of private 
interests, are unlikely to be effective or even de-
fensibly fair. Public sector research programs that 
routinely consign publicly funded research to the 
public domain can attract just as much criticism 
as those programs that seek excessive exclusivity 
in the management of public-funded intellectual 
property. Inattentively letting research outcomes 
fall into the public domain can allow richer and 
more nimble private interests to benefit dispro-
portionately from access to this publicly funded 
knowledge. Public sector IP management must 
therefore be viewed with a strong pragmatic, em-
pirical perspective. Accordingly, an outcome-ori-
ented approach to public interest IP management 
includes:
• promoting an in-house invention disclo-
sure under effective confidentiality rules
• analysis of disclosures in the light of institu-
tional objectives
• assessment of technologies against priori-
ties, categorizing them for public domain 
release or defensive publication, for open 
licensing, for nonexclusive licensing, or for 
a strategic in-house focus
• review of the obstacles to the effective use 
and dissemination of the new technology, 
including resource limitations, regulatory 
obstacles, and constraints on freedom to 
operate in target markets, noting that de-
veloping countries generally have greater 
freedom to operate due to the relatively low 
levels of patenting
• formulation of strategies, and identifica-
tion of potential partnerships, that aim to 
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bring a life-sciences innovation to targeted 
groups, which entails considering commer-
cial, technological, and regulatory issues, as 
well as an assessment of external require-
ments that include background intellectual 
property, project management capacity, 
technological and manufacturing capacity, 
regulatory process capacity, and investment 
capital 
• leveraging intellectual property holdings 
to:
- promote the dissemination of techno-
logical knowledge
- ensure the availability of improvements, 
further applications, and derivatives of 
licensed technology
- secure access to regulatory data and 
background/platform technology
- reserve rights for third-party use in hu-
manitarian applications
- reserve exclusively licensed rights in the 
event that licensees fail to meet public  
interest performance criteria (such as 
low-cost or cross-subsidized distribution 
to target markets)
- safeguard grant-back of background in-
tellectual property, project intellectual 
property, or regulatory dossiers in the  
event that licensees fail to meet public 
interest performance criteria
- bolster institutional research capacity, 
through licensing fees, partnerships, ac-
cess  to research tools and other platform 
technologies 
In the hands of the public sector IP manager, 
an IP portfolio is not necessarily viewed purely as 
a commercial asset, although commercial valua-
tion and product development and dissemination 
will normally be essential. An IP portfolio also 
functions as: 
• a transactional asset, used to promote, expe-
dite, and clarify the formation of technolo-
gy partnerships, and to define and structure 
specific contributions and expectations in 
partnerships
• an institutional asset, used to leverage ac-
cess to necessary resources to achieve 
institutional goals, ranging from specific 
R&D expertise to research financing
• a policy asset, used to influence choices of 
technology partners, including private sec-
tor partners in public–private partnerships, 
and to promote humanitarian or cross-sub-
sidized access to life-science technologies in 
developing countries or in other beneficiary 
groups
The public sector IP manager in the life sci-
ences may also need to consider the public-policy 
expectations placed upon her or him, explicitly, 
implicitly, or even retrospectively. She or he 
should, in particular, consider the following poli-
cy-oriented or systemic responsibilities:
• influencing positive innovation patterns, 
promoting the effective collaboration and 
open dissemination of upstream research 
findings, both for the inherent value of the 
knowledge as a public good and as a means 
of promoting the widest possible applica-
tion of upstream biotechnologies, such as 
research tools, diagnostic tools, and genetic 
modification technologies
• promoting analysis, adaptation, and up-
take of practical-innovation structures that 
make effective use of diverse resources, such 
as strategic partnerships with other public 
institutions, public–private partnerships, 
and open collaborative mechanisms 
• good-faith participation in the patenting 
process, focusing on strategic and systemic 
outcomes, rather than on the tactical use of 
the system, and actively promoting patent 
quality
• fostering an interdisciplinary approach to 
public policy formulation in the life sciences 
and a comprehensive view of the innovation 
process within the broader policy context
• promoting open licensing models for re-
search or for humanitarian uses in pub-
lic health and agricultural development 
programs for the benefit of developing 
countries
Exemplifying the crossover between policy 
and practice is the humanitarian licensing of 
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medical and agricultural research generated by 
universities or other public research institutions. 
“Humanitarian licensing” describes a range of 
public policy licensing strategies. These might 
include providing an open license to developing 
country technology users to sell derivative prod-
ucts back to commercial markets, as in the case of 
agricultural biotechnology. Humanitarian licens-
ing might also mean establishing reach-through 
rights reserving access to derivative innovations 
(for example, for use in licensing early-stage phar-
maceutical research). These practices may be seen 
as a movement to promote certain technology li-
censing norms, even to create de facto exceptions 
to patent rights in the life sciences. They might 
also be imagined as a suite of practical options 
for public sector technology managers to deploy 
in pursuit of institutional objectives. But the 
movement towards humanitarian licensing or re-
serving rights for humanitarian use still begs im-
portant questions at the core of public sector IP 
management:
• How does the deployment of exclusive rights 
over life-science technologies promote the 
public welfare, and when is deployment of 
exclusivity contrary to humanitarian goals 
(the exclusivity axis)?
• To what extent, and how, should public 
sector IP managers engage private interest 
and private sector resources to draw tech-
nologies through a demanding product 
development process, and when will hu-
manitarian interest be enough to impel a 
product through the product pipeline (the 
market axis)?
See Box 2 for a recent exchange that high-
lights the broader range of options open to pub-
lic interest IP managers who have objectives that 
extend beyond the simple commercialization of 
research.
3. puBliC pOliCy ip mAnAgemenT  
in The life SCienCeS 
IP management is not an end in itself, but an es-
sential part of a wider array of policy tools that 
need coordinated implementation to achieve 
desired outcomes. The efficiency and effective-
ness of IP management needs to be measured 
against broader objectives, including its ability 
to complement innovation policy and public in-
vestment in R&D infrastructure. Optimal use of 
intellectual property in the life sciences requires a 
well-managed IP system, clear policies about the 
ownership of intellectual property generated by 
the public sector or from public sector inputs, ad-
equate R&D resources and infrastructure, tech-
nology transfer centers at universities and other 
research institutes, and mechanisms to bring re-
search outcomes to the market. We focus on three 
elements in particular: 
1. Setting the regulatory and policy 
framework
2. Building functioning public institutions
3. Managing public–private partnerships
3.1 The examples of Jordan and Indonesia
3.1.1  Overview
This section reviews information gathered in field 
interviews with practitioners in biomedical in-
novation in two disparate developing countries: 
Jordan and Indonesia. Despite fundamental dif-
ferences in size, structure, resources, and geopo-
litical context, Indonesia and Jordan have both 
set up IP strategies to promote the social benefits 
of domestic biomedical innovation. The countries 
have sought the right institutional framework to 
link IP policy and IP management for the ad-
vance of public welfare. Indonesia is the fourth 
most populous country in the world and, after 
Brazil, is host to the greatest range of biodiversity 
worldwide. Jordan, with four million inhabitants, 
is a relatively small country with little biodiver-
sity, few natural resources, and no oil reserves. 
Both countries have strong potential for bio-
medical innovation. Indonesia’s opportunities are 
linked to the natural medicines market. Jordan’s 
pharmaceutical industry is the country’s second 
largest export earner, after textiles.
Jordan’s pharmaceutical industry is making 
a structural shift from focusing solely on generic 
manufacturing to promoting biomedical inno-
vation. Six out of 12 Jordanian pharmaceutical 
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Box 2: Alternatives to Commercialization in Public Sector IP Management: 
Four Points of View 
According to Tom Ogada, who is responsible for putting in place a formal policy for dealing with 
IP issues at Moi University, “an institutional IP policy serves to promote the generation, protection, 
and commercialization of IP rights. Universities and R&D institutions are key generators of IP assets, 
but there are many stakeholders involved in the process—researchers, students, private sponsors, 
technology transfer units, national patent offices, the public, and so on. An IP policy is needed 
to harmonize the conflicting interests of the various stakeholders.” Thus, a university’s IP policy 
should aim to “create an environment that encourages and expedites the dissemination of new 
knowledge for the greatest public benefit, while protecting the traditional rights of scholars to 
control the products of their scholarly work. It should ensure that the financial or other benefits of 
commercialization are distributed in a fair and equitable manner that recognizes the contributions 
of the inventors and the institution as well as other stakeholders. It should promote, preserve, 
encourage, and aid scientific investigation and research. It should sensitize students to IP and tap the 
creativity of the young. It should create incentives for researchers to conduct research and provide 
rewards for intellectual capital. In developing country universities, it should also stimulate research 
efforts to find solutions for pressing problems, such as medicines, clean water, and energy.”
Dana Bostrom, Industry Alliances Office, University of California, Berkeley, adds that “most 
university technology transfer offices do not have a primary goal of revenue generation. Professor 
Ogada captures the goals of technology transfer well, including: promoting the dissemination of 
knowledge, and assuring stakeholders that risks, benefits and credit are distributed equitably. The 
Association of University Technology Managers (AUTM) does not tend to use revenue generation 
as an indicator of benefit. Rather, [AUTM] uses information about how the university distributes 
revenue received under licenses to benefit the university community; how products which are 
brought to market benefit everyone; and how innovative, university-led licensing programs can push 
an industry or technology forward (among other measures). A blanket give-it-away approach, on 
the other hand, usually benefits large companies, who are able to create and patent improvements 
to the “free” intellectual property more rapidly than other organizations or individuals. For 
developing economies, or early-stage technology of all kinds, “free” can come with a heavy cost. 
Although free intellectual property can still achieve the best outcomes for everyone, this strategy is 
best determined on a case-by-case basis. Without resources to sustain a free commons, often only 
those with resources can benefit from what was released. More than 500 new products became 
available last year as a result of licenses from U.S. and Canadian academic technology transfer 
efforts. More intangibly, universities benefit from the interaction with companies, to see how 
academic thinking and solutions can be applied to commercial problems. Ironically, universities 
also benefit from our academic community’s greater awareness of intellectual property; we live in 
a world where intellectual property plays a greater role, and companies, in their interactions with 
universities, demand greater accountability. Ultimately, universities are increasingly being asked to 
demonstrate to their community the benefit they provide in the knowledge economy.” 
Gavin Moodie, Principal Policy Advisor at Griffith University, Australia, notes that “the 
fundamental question for a public university’s IP policy should not be: ‘How can the commercial 
potential of the property be maximized?’ but ‘How can the transfer of new ideas be maximized?’ 
Commercializing intellectual property is only one way—and often the worst way—to transfer new 
ideas. Concentrating on commercializing intellectual property encourages universities to overvalue 
their property, leading to protracted negotiations using lawyers and other intermediaries, which 
frustrates rather than facilitates the free flow of ideas necessary for research and innovation to 
flourish. Revenue from licensing intellectual property in fields other than biotechnology is a trivial 
(Continued on Next Page)
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proportion of university revenue. And, of course, licensing revenue isn’t all surplus or “profit”—
with their business development managers, IP lawyers, and accountants, commercialization 
units are very expensive. They also impose heavy indirect costs on researchers who must explain 
their research and its implications to intermediaries. Joshua B. Powers reported in The Chronicle 
of Higher Education (September 22, 2006) that more than half of U.S. universities consistently 
lose money on technology transfer. And as the Australian policy and management consultant 
John Howard observes, researchers and research organizations will, except in very rare 
situations, earn more from being paid for their work input in contracts and consultancies than 
from licenses and royalties flowing from intellectual property or from income earned in spinout 
companies. I therefore suggest that—with the exception of biotechnology—public universities 
simply give away most intellectual property as a contribution to the general good. This could 
be subject to universities including in their IP licensing agreements a standard “blockbuster” or 
“jackpot” clause that provides that should their intellectual property contribute to blockbuster 
revenues of, say, $50 million over 10 years, there would be a sharing of revenue determined by a 
nominated commercial arbitrator.” 
Bernardo Marcos Diez, Secretariat for Technology Transfer (New Technologies Research Group), 
Faculty of Law, Universidad Nacional de Mar del Plata, Argentina, advised that the Governing 
Council of the University had “recently approved a regulation which defines the scope, players, 
and procedures regarding the protection of any intellectual creation resulting from scientific or 
cultural research carried out within the university and/or with third parties. We have adopted an 
active IP awareness policy to reach those involved in this process, from the researchers, teaching 
staff, and students, to members of the decision-making bodies. We are running conferences in 
the different academic units in order to explain the objectives, implications, and advantages 
of IP protection, as well as of technology transfer between the university and external social/
commercial milieu. We have also applied to join the WIPO University Initiative in order to appoint 
a coordinator and benefit from relevant IP reference materials. So we are in the early phase of 
what will be a lengthy process, but one which, it is already clear, will bring economic, scientific 
and developmental benefits, not only to our university, but also to our broader society.” 
Source: WIPO Magazine.10
Box 2 (continued)
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companies have now developed patent portfo-
lios, several of which are potential blockbusters 
(remarkably, until recently most of these com-
panies made no use at all of the patent system). 
Indonesia is taking several measures to bolster its 
overall innovation strategy. It is, for instance, pro-
moting awareness among public research institu-
tions and the private sector of the opportunities 
in the natural medicines market. This market of-
fers annual growth rates as high as 20%. 
These countries are steadily increasing their 
IP holdings on indigenous research activities, 
particularly in the critical areas of the life sci-
ences: medical and agricultural research. As they 
do, broad public interest issues arise. How can 
or should private firms be encouraged to man-
age their IP holdings to contribute optimally 
to national social and economic development? 
Additionally, how can public sector or public-
funded IP estates be best managed to safeguard 
the public interest by capturing and equitably 
distributing the benefits of innovation? Finally, 
what broader institutional settings are needed to 
bolster public welfare outcomes from research? 
A public interest IP management perspective 
can help technology transfer centers at public 
research institutions find answers to these ques-
tions. Additionally, effective IP management en-
courages public–private partnerships that address 
humanitarian goals, in particular, the creation of 
affordable new medicines. 
The experiences of both Indonesia and 
Jordan illustrate the broader need for appro-
priate domestic institutional settings in order 
for the countries to be able to reap the benefits 
of biomedical innovation. Their experiences 
of Indonesia and Jordan also reveal the im-
portance of the interplay between investment 
in institutional infrastructure and the more 
diverse and tailored approaches to managing 
intellectual property within a public interest 
paradigm. The discipline of IP management 
has focused on the needs of firms. However, 
the high level of public concern with capturing 
public benefits from life-sciences research un-
derscores that countries, and public sector in-
stitutions, also need to make strategic decisions 
about the deployment of intellectual property 
on a broader base than the traditional focus of 
private firms. 
3.1.2  Setting the regulatory framework 
IP law and practice cannot be viewed in isolation 
from the broader regulatory context. This is es-
pecially true in the field of life sciences, which is 
concerned with needs as basic as health, food, and 
the environment. Public interest IP management 
in biomedical innovation therefore needs to rec-
oncile public health needs with commercial goals, 
ideally helping to harness private sector resources 
to achieve public welfare outcomes.
Indonesia and Jordan have effective IP leg-
islation in place, and both have undertaken ex-
tensive legislative programs to bring their laws 
into compliance with the TRIPS Agreement. 
Indonesia also adhered to the PCT in 1997, and 
Jordan has entered a bilateral trade agreement 
with the United States, which has implications 
for Jordan’s IP laws. In both countries, IP policy 
has been developed in an interdisciplinary way, 
as part of a broader public policy mix, rather 
than as a narrow, specialized discipline. Jordan’s 
Ministry of Planning is responsible for coordi-
nating public policies regarding innovation, and 
for measuring Jordan’s global competitiveness 
in achieving this goal. Jordan’s main innovation 
policy, King Abdullah II’s Vision 2020, proposes 
the strategic use of IP mechanisms to achieve 
society’s goals. Likewise, Indonesia coordinates 
intellectual property across policy portfolios, in 
cooperation with the Ministry of Research and 
the Directorate General of Intellectual Property, 
which screens research grants given to public re-
search institutions and conducts patent searches, 
supplementing the conventional literature review. 
Indonesia also provides funding to patent appli-
cants to make patent protection more affordable 
to local companies and public research institu-
tions, which is one way to address the issue of 
practical equity in access to the IP system. 
Jordan is reviewing possible legislative ini-
tiatives regarding the management of intellec-
tual property generated in public institutions. 
Indonesia has passed laws that give ownership 
over intellectual property generated within 
public research institutions to the institutions 
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themselves. This regulatory measure has been ac-
companied by the establishment of technology 
transfer offices (TTOs). Ten TTOs were created 
throughout the country with modest start-up 
capital. The offices have confounded some expec-
tations by establishing successful business opera-
tions in recent years. The Technology Institute of 
Bandung, for example, has struck international 
licensing agreements and research collaborations 
with local companies that are actively seeking to 
meet local needs. One public-private partnership 
resulted in the development of a new machine for 
harvesting local agricultural crops.
3.1.3  Building accountable and  
effective public institutions 
The benefits of the regulatory framework will 
depend on establishing public institutions that 
are both accountable to the public and effective 
in serving it. These obligations go beyond the 
traditional institutional objectives of IP offices 
concerning administration of the patent system. 
Their responsibilities broaden into a wider policy 
role in the knowledge economy. IP mechanisms 
are actively harnessed to promote the overarch-
ing public interest. In both Indonesia and Jordan, 
the IP office reports to the ministries responsible 
for commerce and industry. This helps align IP 
policy with the countries’ overall economic and 
trade policy objectives. As in all countries, there 
are important choices to be made between the 
value of administrative independence, self-suf-
ficiency and direct accountability to political 
masters, and the benefits of linkages to a major 
policy ministry that can encourage high-level 
political attention to IP policy-making. In both 
Jordan and Indonesia, the IP offices focus on the 
operational challenges of using limited resources 
to serve diverse stakeholders. The two offices dif-
fer in size: Indonesia currently deals with a higher 
patent filing rate (4,303 applications in 2005); it 
was reported that Jordan had 200. But Indonesia 
confronts a problem experienced in many devel-
oping countries–that of finding and retaining 
suitably qualified technical staff to deal with the 
increasingly complex field of life sciences, effec-
tive examination capacity being one important 
safeguard of patent quality. 
3.2 Managing public–private partnerships 
Life sciences R&D is often characterized by up-
stream, or basic, research conducted by public 
sector or academic researchers. Public sector in-
stitutions then depend on the private sector to 
take life-sciences innovations through the devel-
opment pipeline to yield finished products. Thus, 
life-sciences innovation pathways are increasingly 
characterized by an array of public–private part-
nerships. Those conducting early research and 
those investing in the product development phase 
will naturally have different approaches to the re-
lationship. But because life-sciences research has 
such a strong public interest element, close atten-
tion has been paid to how to manage intellectual 
property for specific public interest outcomes. 
Public sector research institutions are learning 
to pursue the option of leveraging their IP hold-
ings to ensure adequate returns from public in-
vestment in research, whether those returns are 
conceived in terms of narrow financial benefits or 
broader social ones. And public sector IP manag-
ers are trying to ensure that promising innova-
tions are not left on the shelf for want of practical 
mechanisms to garner the necessary resources—
finance, expertise, regulatory approval capacity, 
product development, and manufacturing know-
how. TTOs, situated within universities, have 
also discovered the dual goal of helping to meet 
humanitarian needs and to mediating between 
academics and the market, which ultimately may 
determine a society’s capacity to nurture innova-
tion based growth.
The interaction between the public and the 
private sector in health innovation can result 
in philanthropic achievements that also satisfy 
business interests. Successful examples of this in 
the field of public health include the Medicines 
for Malaria Initiative, the Drugs for Neglected 
Disease Initiative, PATH, One World Health, 
and the Bill and Melinda Gates Foundation. 
Publicly funded innovation provides an ad-
ditional mission and incentive system for busi-
nesses. A tension is usually perceived to arise 
between research and development. Research 
is often guided by the search for new insights; 
market interests are generally of secondary rel-
evance. In development, however, the market is 
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the defining element, since the substantial costs 
and risks associated with the development of new 
products and services can often only be justified 
by expected earnings.11 Currently, research tends 
to be concentrated in the public sector, whereas 
development is most often left to business. The 
relationship between research and development 
is usually mediated by the protection and subse-
quent exchange of intellectual property between 
the public and private sectors. This means that it 
is crucial to establish equity and negotiating sym-
metry between these sectors, bridging between 
distinct sets of goals and cultural settings. By 
using the IP system, public research institutions 
avoid giving away valuable knowledge without 
maintaining some leverage over how it is devel-
oped and disseminated, and without securing 
an adequate return, whether that return is in the 
form of money or social return. In this way, intel-
lectual property provides a mechanism to achieve 
equity with the private sector. 
Motivating researchers to patent innovation 
judiciously is an essential part of participating 
in the IP system, and institutions need to raise 
awareness about the necessity and advantages of 
an active but selective patenting strategy. Incentive 
structures for academics often help to pave the 
way from the research lab to the TTO. One way 
to achieve this is to allow academics to generate 
additional revenues from consulting agreements, 
royalties, and licensing agreements. Clearly, this 
should not provide businesses the opportunity 
to dictate the research agenda of public research 
institutions, nor should it compromise the funda-
mental freedom of research. Institutional policies 
need to protect these values. Nevertheless, relax-
ing the institutional restrictions on the interaction 
between the public sector and business in health-
related innovation might allow public research 
to generate new questions and find alternative 
approaches to a subject. Engagement in product 
development in health-related innovation has 
proven to be a valuable experience that enhances 
the quality of basic research. Faculty, for example, 
might develop innovative insights while resolving 
problems encountered in industrial consulting. 
Mansfield found that coauthorship by indus-
try and academics increased the overall research 
productivity in health-related innovation, con-
cluding that such activity can bring a new sense 
of urgency and reality to the public sector.12 In 
Sweden, for example, 10% of articles on health-
related innovation are coauthored by scientists 
working in the private sector.13 Government 
funding for such exchanges can provide a useful 
push to such initiatives. Austria illustrates how 
such a program can operate. In Austria, academ-
ics have the opportunity to spend a year or two 
in a company and then return to their university. 
They are guaranteed their post and granted fund-
ing for the exchange. 
To obtain the best outcomes for public 
health, researchers and institutions must under-
stand the value of intellectual property, commu-
nicate the worth of their intellectual property to 
potential trading partners, negotiate attractive 
licensing agreements, and enter agreements that 
will generate appropriate returns. IP manage-
ment comprises several components, including 
the prioritization and identification of research 
targets, decisions as to whether and which form 
of IP protection to seek, and methods to gain the 
attention of prospective investors/buyers of the 
product. 
Technology transfer centers within public re-
search institutions fill an important role in secur-
ing IP rights. They help researchers understand the 
need for intellectual property, give support in the 
application for IP protection, and help to transfer 
research results to the market. As in many other 
developing countries, the staff at these centers 
needs IP management training. In fact, a train-
the-trainers program is often needed to enhance 
IP management competencies. An exchange with 
IP management centers in the developed world 
may, in this context, be beneficial. 
To accomplish all of this, researchers and pub-
lic institutions need to identify potential licens-
ees, facilitate research collaboration, pool patents, 
and avoid unnecessary duplication. Other ways 
of encouraging public–private partnerships in-
clude commissioning research projects, operating 
joint research studies, financing doctoral studies 
with industrial laboratory funds (with due regard 
to the needs of the doctoral student to publish 
results), encouraging faculty consulting work, 
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and creating spinout companies. Establishing 
research clusters, in which public and private 
sector researchers and institutions work on com-
mon research projects, provides opportunities 
to exchange both tacit knowledge (know-how) 
and formal knowledge (such as publications and 
patents). Through the provision of a clear, trans-
parent regulatory framework and publication of 
basic research, anticompetitive problems can be 
avoided. 
From a health-equity point of view, the ef-
fectiveness of licensing agreements will depend 
on the conditions negotiated in these agreements 
and the overall innovation market. Licensing can 
lessen competition and raise anticompetition is-
sues, even when there is no cumulative aspect. 
Exclusive licensing arrangements may hamper 
public health if the cost reduction of one mar-
ket participant forces competitors to exit the 
market, or if the licensing agreement facilitates 
collusion.14 
Indonesia and Jordan both report positive 
experiences with public–private partnerships in 
biomedical innovation. Indonesia has developed 
an excellent framework for public–private part-
nerships. The Indonesian Science Foundation 
(LIPI) may be taken as a best practice example 
of public interest IP management. LIPI provides 
IP courses for its researchers, has developed its 
own in-house IP policy, and manages an active 
technology transfer center that has already issued 
several licenses. LIPI has also entered into allianc-
es with research institutions abroad, such as the 
Max Planck Institute, with whom jointly gener-
ated intellectual property is jointly owned. 
Technology transfer centers in Indonesia 
are attached to research institutions, such as 
public universities or research organizations. 
These technology transfer centers use different 
names, such as Gugus HaKI (IP Units), Sentra 
HKI (IPR Centers), Klinik HKI (IPR Clinics), 
IPR Management Office, or IPR, and Licensing 
Office. With the exception of the Eijkman 
Institute, all major public research institutions 
dealing with biomedical innovation have their 
own technology transfer center. The extent of the 
activities carried out by these centers varies from 
the most advanced, which provide assistance on 
IP licensing agreements, to those that assist pri-
marily with applying for IP protection or helping 
raise awareness about intellectual property among 
researchers. The statutes of Indonesia’s technology 
transfer offices suggest very clearly that intellectu-
al property held by public institutions should be 
licensed under a public interest paradigm.
In Jordan, there are several examples of fac-
ulty–private sector biomedical R&D collabora-
tive projects, but the emphasis so far has been 
on research led by the private sector. Discussions 
reportedly continue regarding a suitable frame-
work for the ownership of innovation created in 
the public domain. The Royal Scientific Society 
of Jordan has an applied, rather than a research, 
orientation. 
Jordanian universities do not have TTOs to 
administer patent applications or negotiate licens-
ing agreements. However, companies increasingly 
refer to universities as subcontractors for specific 
biomedical tests. So far, the universities provide 
skilled labor and conduct some basic research. 
These activities appear to promise more institu-
tionalized partnerships and the beginning of a rela-
tionship between academia and the private sector. 
4. COnCluSiOnS: ReCOnCiling pOliCy 
And pRACTiCe
4.1 Exclusivity or inclusion: public 
or private interest? 
The long history of patent law and patent policy 
has been a dynamic record of attempts to recon-
cile two complementary goals:
1. The promotion of innovation by directing 
resources toward beneficial research and 
development
2. The practical and equitable availability of 
the fruits of innovation
Public interest IP management in the life sci-
ences is itself a search for practical means of achiev-
ing these twin goals. It seeks first to garner neces-
sary resources and then to focus them on finding 
technological solutions to neglected needs in the 
public health and agricultural domains. The tangi-
ble and intangible resources required for IP devel-
opment include know-how, research, and product 
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development capacity, clinical or field trial exper-
tise, regulatory infrastructure, background/plat-
form technologies, and the investment of public 
and private capital. IP management strategies will 
be effective if they help to apply these resources 
toward unmet needs. This requires finding these 
resources via new private resources (such as incen-
tives and market interventions) and via new public 
resources (additional funding and infrastructure 
development). IP managers must also work to 
better apply existing resources by leveraging access 
to technologies and by drawing on private sec-
tor development skills and R&D infrastructure, 
indigenous research and innovation capacity, and 
traditional medical knowledge. 
It is tempting to argue that the traditional 
conception of two distinct public and private 
spheres in the life sciences is breaking down. But 
it is more accurate to characterize it as a form of 
evolution, a broadening of the scope of inter-
action, and the creation of a far-broader policy 
canvas that can accommodate more geographical, 
cultural, and economic diversity in the use of the 
patent system. Figure 1 (see section 1.2 above), 
as discussed earlier, illustrates the options for IP 
management in pharmaceutical product develop-
ment. The figure illustrates how workable mecha-
nisms for bringing new biomedical innovations 
to the public may require (1) a range of strategic 
choices to engage or eschew market mechanisms 
to various degrees in order to secure the necessary 
resources and freedom to operate, rather than 
electing a wholly “public” or “private” technol-
ogy development and dissemination model, and 
(2) deployment of exclusive rights afforded by IP 
protection to greater or lesser degrees of exclu-
sivity and openness, ranging from direct exclu-
sive exploitation or exclusive licensing, through 
a range of options of decreasing exclusivity, to 
simple public-domain disclosure.
Though it may seem counterintuitive, some 
public sector technology-development strategies 
may require exceptional degrees of exclusivity. This 
may be useful, for example, when seeking access to 
a private sector compound library or when nego-
tiating access to an existing regulatory dossier. In 
contrast, as the SNP consortium (single-nucleo-
tide polymorphism) and the human genome proj-
ect have demonstrated, private sector players may 
see commercial advantage in deploying nonexclu-
sive IP management structures, particularly for 
technologies that are considered precompetitive. 
No single template is likely to be anything but an 
indicative guide or catalog of options. Ultimately, 
good practice is good policy: the same exclusive 
right may be viewed very differently if it is held 
by a private firm, by a public sector agency, or by 
a private charity. Equally, the exclusive right will 
be viewed very differently depending on how it is 
deployed in practice.16
4.2 Fostering interdisciplinary IP policies 
Indonesia and Jordan provide complementary 
and contrasting examples of the role of judicious 
institutional settings in promoting investment in 
life-sciences research, tailored to the social and 
economic needs of developing countries. A coun-
try’s capacity to set up an effective institutional 
framework for public-interest-minded intellec-
tual property is the decisive factor. Used in an ef-
fective, informed and judicious manner, it creates 
a positive link between the exercise of exclusive 
commercial rights and a fairer distribution of 
the benefits of technological advancement, with 
strategies carefully tailored to a country’s level of 
wealth or economic development. ■
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